<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>LMP2A is expressed in latent Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and interacts with LMP1 and members of the src tyrosine kinase family in the plasma membrane </plain></SENT>
<SENT sid="1" pm="."><plain>Since tyrosine kinase mediate receptor-induced changes in intracellular free calcium, the effect of LMP2A on receptor-mediated intracellular calcium mobilization was evaluated by stably expressing LMP2A in an EBV-negative <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> cell line (BJAB) or in LMP1-converted BJAB cells </plain></SENT>
<SENT sid="2" pm="."><plain>LMP2A significantly blocked calcium mobilization following class II, CD19, or immunoglobulin M cross-linking </plain></SENT>
<SENT sid="3" pm="."><plain>LMP2A effects were partially reversed in LMP1-converted cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>These results are compatible with LMP2A acting in latent B-lymphocyte <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> to downmodulate LMP1 effects on cell growth or to inhibit induction of lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in specific human tissues following receptor ligation </plain></SENT>
</text></document>